Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Innovent Biologics ( (HK:1801) ) has shared an update.
Innovent Biologics has announced the inclusion of seven innovative drugs in China’s updated 2025 National Reimbursement Drug List (NRDL), which will be effective from January 1, 2026. This inclusion covers key disease areas such as oncology and cardiovascular diseases, enhancing patient access and affordability. The announcement underscores Innovent’s commitment to providing pioneering treatments and improving healthcare outcomes in China, potentially benefiting a large number of patients and families.
The most recent analyst rating on (HK:1801) stock is a Hold with a HK$101.00 price target. To see the full list of analyst forecasts on Innovent Biologics stock, see the HK:1801 Stock Forecast page.
More about Innovent Biologics
Innovent Biologics, Inc. is a biopharmaceutical company focused on developing and commercializing high-quality, affordable medicines. The company operates in the fields of oncology, cardiovascular and metabolic diseases, autoimmune disorders, and ophthalmology, aiming to address significant public health challenges and improve drug accessibility and affordability.
YTD Price Performance: 151.37%
Average Trading Volume: 16,249,777
Technical Sentiment Signal: Buy
Current Market Cap: HK$157.7B
For an in-depth examination of 1801 stock, go to TipRanks’ Overview page.